BRIDGEWATER, N.J.--(BUSINESS WIRE)--Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) today announced strong first quarter 2008 financial results. For the three months ended March 31, 2008, Enzon reported a net income of $1.5 million or $0.03 per diluted share, as compared to a net loss of $2.8 million or $0.06 per diluted share for the first quarter of 2007. The Company’s first quarter 2008 results were positively impacted by strong revenues across all business segments.
